Ronald Omino1, Sahil Mittal2,3,4,5, Jennifer R Kramer2,4, Maneerat Chayanupatkul3,5, Peter Richardson2,4, Fasiha Kanwal2,3,4,5. 1. Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Ronald.Omino@bcm.edu. 2. Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, 2002 Holcombe Blvd. (152), Houston, TX, 77030, USA. 3. Sections of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, USA. 4. Sections of Health Services Research, Baylor College of Medicine, Houston, TX, USA. 5. Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: Administrative databases that include diagnostic codes are valuable sources of information for research purposes. AIM: To validate diagnostic codes for hepatocellular carcinoma (HCC) in chronic hepatitis B patients. METHODS: We conducted a retrospective study of patients with chronic HBV seen in the national Veterans Administration (VA). HCC cases were identified by the presence of ICD-9 code 155.0. We randomly selected 200 HBV controls without this code as controls. We manually reviewed the electronic medical record (EMR) of all cases and controls to determine HCC status. We calculated the positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity for the HCC code. We conducted an implicit review of the false-positive cases to determine possible reasons for the miscoding. RESULTS: Of the 8350 patients with HBV, 416 had an ICD-9 code for HCC. Of these 416, 332 patients had confirmed HCC and 61 did not; HCC status was indeterminate for 23 patients. Of the 200 controls, none had HCC confirmed in the EMR. The PPV ranged from 85.3 to 80.0% and specificity ranged from 99.2 to 99.0% based on classification of indeterminate cases as true versus false positives, respectively. The NPV, sensitivity, and specificity were 100%. Two-thirds of false-positive cases were diagnosed with HCC prematurely as a workup of liver mass and latter imaging and/or biopsy were not diagnostic for HCC. CONCLUSION: The diagnostic code of HCC in chronic HBV patients in the VHA data is predictive of the presence of HCC in medical records and can be used for epidemiological and clinical research.
BACKGROUND: Administrative databases that include diagnostic codes are valuable sources of information for research purposes. AIM: To validate diagnostic codes for hepatocellular carcinoma (HCC) in chronic hepatitis Bpatients. METHODS: We conducted a retrospective study of patients with chronic HBV seen in the national Veterans Administration (VA). HCC cases were identified by the presence of ICD-9 code 155.0. We randomly selected 200 HBV controls without this code as controls. We manually reviewed the electronic medical record (EMR) of all cases and controls to determine HCC status. We calculated the positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity for the HCC code. We conducted an implicit review of the false-positive cases to determine possible reasons for the miscoding. RESULTS: Of the 8350 patients with HBV, 416 had an ICD-9 code for HCC. Of these 416, 332 patients had confirmed HCC and 61 did not; HCC status was indeterminate for 23 patients. Of the 200 controls, none had HCC confirmed in the EMR. The PPV ranged from 85.3 to 80.0% and specificity ranged from 99.2 to 99.0% based on classification of indeterminate cases as true versus false positives, respectively. The NPV, sensitivity, and specificity were 100%. Two-thirds of false-positive cases were diagnosed with HCC prematurely as a workup of liver mass and latter imaging and/or biopsy were not diagnostic for HCC. CONCLUSION: The diagnostic code of HCC in chronic HBV patients in the VHA data is predictive of the presence of HCC in medical records and can be used for epidemiological and clinical research.
Authors: Fasiha Kanwal; Tuyen Hoang; Jennifer R Kramer; Steven M Asch; Matthew Bidwell Goetz; Angelique Zeringue; Peter Richardson; Hashem B El-Serag Journal: Gastroenterology Date: 2010-12-22 Impact factor: 22.682
Authors: Susan E Andrade; Jerry H Gurwitz; K Arnold Chan; James G Donahue; Arne Beck; Myde Boles; Diana S M Buist; Michael Goodman; Andrea Z LaCroix; T R Levin; Richard Platt Journal: J Clin Epidemiol Date: 2002-03 Impact factor: 6.437
Authors: J R Kramer; J A Davila; E D Miller; P Richardson; T P Giordano; H B El-Serag Journal: Aliment Pharmacol Ther Date: 2007-11-08 Impact factor: 8.171
Authors: Elizabeth E Powell; Patricia C Valery; Kelly L Hayward; Amy L Johnson; Benjamin J Mckillen; Niall T Burke; Vikas Bansal; Leigh U Horsfall; Gunter Hartel; Chris Moser Journal: BMJ Open Gastroenterol Date: 2020-09
Authors: Maria Assunta Zocco; Francesca Romana Ponziani; Mariella Faccia; Francesco Santopaolo; Antonio Gasbarrini; Maurizio Pompili Journal: Intern Emerg Med Date: 2022-01-25 Impact factor: 5.472